The global cancer biomarkers market size is evaluated at USD 15.58 billion in 2025 and is forecasted to exceed over USD 43.05 billion by 2034, growing at a CAGR of 11.99% from 2025 to 2034.
In terms of revenue, the worldwide market of cancer biomarkers was valued at USD 13.87 billion in 2024. The North America cancer gene therapy market size was estimated at USD 4.99 billion in 2024 and is expanding at a CAGR of 12.02% during the forecast period.
The demand for personalized medicines has increased due to the rising prevalence of chronic and rare diseases, making it an essential approach in cancer biomarkers. Increasing adoption of liquid biopsies is driving significant growth in the market. Moreover, regulatory support for collaborative approaches to boost cancer biomarker settings is leveraging the growth.
This Report is Readily Available for Immediate Delivery | Download the Sample Pages of this Report@: https://www.precedenceresearch.com/sample/1637
Cancer Biomarkers Market Key Takeaways
• North America led the global market with the largest market share of 36% in 2024.
• The breast cancer segment has captured the biggest market share in 2024.
• The diagnostics segment contribute the biggest revenue share in 2024.
• The genetic biomarkers segment registered the maximum market share in 2024.
Market Overview and Industry Potential
The rising prevalence of cancer worldwide is driving demands for personalized medicines requiring significant biomarkers to approach advanced target therapies. The demand for personalized medicines makes essential approaches toward tailored therapies for individual patients to improve outcomes. Additionally, technological advancements such as next-generation sequencing and AI-enable diagnostic platforms are transforming the accuracy of diagnostic solutions.
With the growing adoption of liquid biopsy and the integration of cutting-edge technologies with drug discovery and development platforms, the cancer biomarkers market is expected to witness more growth in the upcoming period. Advancements in existing technologies are providing access to advanced versions of treatment solutions. The cancer biomarkers market is further anticipated to grow due to increasing utilization in drug discoveries and developments.
• In 2025, the Surface acoustic wave (SAW) sensor technology is projected to approach diagnosing cancer through the detection of cancer biomarkers by its high sensitivity, potential label-free operation, and fast response times, and, fundamentally, because of its non-invasive techniques.
Artificial Intelligence (AI) Catapults the Medical Biomarkers Industry into the Future
Artificial Intelligence (AI) implementation in biomarkers is a significant step in improving the discovery of novel biomarkers, improving accuracy, and advancing personalized medicine approaches. It provides a more detailed and nuanced analysis of patient data to provide a better understanding of specific treatment requirements.
AI is a potential tool that can be reliable for the discovery speed and accuracy of cancer biomarkers. Ongoing innovations for advancing the facilitation of AI in clinical research are transforming the clinical markets, including cancer biomarkers. Novel adaptive approaches to boost detection and diagnostic technologies with AI integration are leveraged for further market expansion.
• According to a study performed by researchers at the Johns Hopkins Kimmel Cancer Center in collaboration with several other institutions in the United States and Europe in September 2024, A blood test using artificial intelligence (AI) to detect cancer-related genetic changes and protein biomarkers can help screen women for early signs of ovarian cancer.
Key Trends
Increasing use of Biomarkers
The rising prevalence of cancers is leading to innovations and developments of new drugs and treatment solutions. Biomarkers are essential for identifying potential targets for drug discovery and development. Rising drug discovery and development activities are surging the adoption of biomarkers to improve the efficacy, safety, predictiveness, and prognostic value of novel drugs.
Additionally, biomarkers used in drug discovery and development help to improve patient stratification by allowing special treatment solutions for specific patients to enhance outcomes.
Collaborative Approaches
Government and regulatory investments in research and development and collaborative approaches between key market companies, research institutes, and academic institutes are playing favorable roles in market expansion. Companies are partnering with research institutes and providing strategic investments to enable access to non-invasive diagnosis and improve accuracy, accessibility, and personalized treatments.
Key market companies are surging collaborations with research institutes for the development of novel, innovative cancer biomarkers. These approaches are taking place due to the increased need for personalized medicines.
View Full Report@ https://www.precedenceresearch.com/cancer-biomarkers-market
Cancer Biomarkers Market Report Coverage
|
Report Attribute |
Key Statistics |
|
Market Size in 2025 |
USD 15.58 Billion |
|
Market Size by 2034 |
USD 43.05 Billion |
|
CAGR from 2025 to 2034 |
11.99% |
|
Leading Region |
North America |
|
Base Year |
2024 |
|
Forecast Period |
2025 to 2034 |
|
Segments Covered |
Type, Biomolecule, Profiling Technology, End User, Application, and Regions |
|
Regions Covered |
North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Set up a meeting at your convenience
to get more insights instantly! https://www.precedenceresearch.com/schedule-meeting Key Regional Analysis What is the market size of Cancer Biomarkers in U.S.? The
U.S. cancer biomarkers market size reached USD 3.44 billion in 2023 and is
expected to expand around USD 11.16 billion by 2034, at a CAGR of 12.49% from
2025 to 2034. North
America dominates the global cancer biomarkers market due to the well-established
research sector, government and regulatory investments in research and
development activities, the rising prevalence of cancer, and the presence of
major key players. The United States is leading the regional market with high
cancer prevalence in the country. The increased prevalence of cancer has led to
the demand for personalized medicines, having a crucial influence on biomarker
adoption and discovery. The
presence of competitive landscapes and the availability of significant funding
generate further market expansion in the country. Government initiatives allow
companies, research institutes, and academic institutes collaborative
approaches to advance the discovery, utilization, and development of novel
cancer biomarkers. • In January 2025, Quanterix
Corporation, a company fueling scientific discovery through ultra-sensitive
biomarker detection, collaborated with Akoya Biosciences, The Spatial Biology
Company® for a signed agreement that Quanterix will acquire Akoya in an
all-stock transaction. This transaction is projected to develop the first
integrated solution for ultra-sensitive detection of blood- and tissue-based
protein biomarkers. Asia
Pacific accounted to witness significant growth in the forecast period. This
projection is majorly highlighted due to the rising awareness of cancer
biomarkers in the region. China, India, and Japan are the major countries
leading the Asian cancer biomarkers market. Japan is leading the market with
countries with a high aging population and a high risk of cancer among them. China
and India are leading markets because of countries vast population, growing
cancer incidence, especially breast and lung cancers, and approach toward
cutting-edge technologies. The rising adoption of personalized medicines,
advanced cancer diagnosis and therapies, and government funding for research
and development are creating market success. Cancer Biomarkers Market Segmentation Analysis Type Analysis The
breast cancer segment dominated the cancer
biomarkers market in 2024. The segment growth is majorly attributed to the
increased incidence of breast cancer. High demand for early detection and
diagnosis of breast cancer has led the segment to boost the utilization of
biomarkers. Ongoing innovations for the development of novel advanced
biomarkers to detect early risk of breast cancer are significant in the breast
cancer segment. Moreover, the increased adoption of liquid biopsy in breast
cancer is driving segment expansion. However,
the lung cancer segment will grow rapidly due to rising lung cancer prevalence
in the aging population. The rising need for the adoption of advanced
diagnostic technologies, including biomarkers for lung cancer, is emerging in
the market. Furthermore, the ongoing emphasis on the utilization of biomarkers
for the identification of tumors to develop target therapies for advancing lung
cancer diagnosis significantly impacts the market growth. • In
August 2024, the American Lung Association's State of Lung Cancer unveiled
insurance coverage for comprehensive biomarker testing for 15 states Biomolecule Analysis The
genetic biomarkers generated the biggest share of the cancer biomarkers market in
2024. Biomarkers enable precisely identifying genetic mutations linked to
cancer, which provides early detection and diagnosis. Genetic biomarkers are
highly efficient and effective in cancer diagnosis and treatment. The
implementation of advanced technologies like next-generation sequencing and the
demand for personalized medicines are driving emphasis on genetic biomarkers.
Moreover, growing research and development efforts to discover new genetic
biomarkers to improve diagnostic tests are driving the market. On
the other hand, the epigenetics segment accelerated its growth. This growth is
accounted for by the novel approach of epigenetic biomarkers for early cancer detection,
prognosis prediction, and personalized treatment monitoring. Epigenetic
biomarkers are beneficial for advanced diagnosis approaches and monitoring of
various cancers such as breast, lung, and colon cancer. Profiling Technology Analysis The
imaging technologies segment accounted for the largest market share with the
growing utilization of imaging technologies for early detection, diagnosis, and
treatment monitoring. The need for personalized cancer management strategies
further drives the adoption of imaging technologies due to their ability to
visualize and characterize tumors in real-time. Computed tomography,
ultrasound, mammography, and magnetic resonance imaging are trending in the
market. The
immunoassays will gain a significant market share in the coming years.
Immunoassay profiling technology provides a highly sensitive and specific
method for the detection of various cancer portions, which allows for early
detection, diagnosis, and personalized treatment settings. This technology
provides multiplexing capabilities for measurements of multiple biomarkers for
a better understanding of cancer biology. The rising utilization of immunoassay
technology in research and clinical settings is driving the segment growth. Application Analysis In
2024, the diagnostics segment led the global cancer biomarkers market because
of increased demand for advanced diagnostic technologies to treat the rising
prevalence of cancer. The government has been focusing on promoting awareness
of cancer and providing funding for research institutes. Growing advancements
in cancer biomarkers-based diagnostics tests are being enabled thanks to
government and regulatory initiatives and investments in research and
development. Moreover, the implementation of cutting-edge technologies like AI
and ML is enabling advanced cancer biomarkers-based diagnostics. The
personalized medicine segment will grow rapidly in the coming years. The
segment growth is accounted for by the increased demand for personalized
medicines to treat an individual patient based on their genetic experiences.
Growing awareness of personalized medicines among healthcare professionals and
patients is surging demands. Companies are investing in innovations and
developments of personalized medicines to provide advanced approaches in the
healthcare sector. The surge in personalized medicines is driving the need for
biomarkers. End-user Analysis The
hospital's segment dominated the market due to the rising prevalence of cancer
and patient hospitalizations. Healthcare professionals majorly use biomarkers
for the detection and diagnosis of various cancers. Rising demand for liquid
biopsy for breast cancers is a significant factor contributing to segment
growth. Additionally, technological advancements in diagnostics, such as
next-generation sequencing, are offering advanced cancer diagnostic services in
hospitals. Government funding and insurance availability for cancer make
hospitals a priority choice for patients. However,
the academic and cancer research institutes segment is projected to grow
rapidly in the upcoming period. Growing collaborative approaches between
research institutes and academic institutes are leveraging for the development
of advanced and innovative cancer biomarkers. Government funding for academic
and cancer research institutes is allowing the adoption of cutting-edge
technologies that improve the facility of cancer biomarkers. Moreover, the
growing utilization of cancer biomarkers for novel drug discovery and
development is driving the segment to grow. Browse More Insight: 🔸Personalized Medicine
Biomarkers Market: https://www.precedenceresearch.com/personalized-medicine-biomarkers-market 🔸Predictive Biomarkers
Market: https://www.precedenceresearch.com/predictive-biomarkers-market Genomic Biomarker Market: https://www.precedenceresearch.com/genomic-biomarker-market 🔸Neurological Biomarkers
Market: https://www.precedenceresearch.com/neurological-biomarkers-market 🔸Cancer Therapeutics
Market: https://www.precedenceresearch.com/cancer-therapeutics-market 🔸Multiplex Biomarker
Imaging Market: https://www.precedenceresearch.com/multiplex-biomarker-imaging-market 🔸Oncology Market: https://www.precedenceresearch.com/oncology-market 🔸Cancer IVD Market: https://www.precedenceresearch.com/cancer-ivd-market 🔸Oncology Molecular
Diagnostic Market: https://www.precedenceresearch.com/oncology-molecular-diagnostic-market 🔸Precision Oncology Market:
https://www.precedenceresearch.com/precision-oncology-market 🔸Cancer Immunotherapy Drug
Discovery Outsourcing Market: https://www.precedenceresearch.com/cancer-immunotherapy-drug-discovery-outsourcing-market Cancer Biomarkers Market Companies •
Illumina Inc. •
Bio-Rad Laboratories Inc. •
Thermo Fisher Scientific Inc. •
F. Hoffmann-La Roche Ltd. •
QIAGEN N.V. •
Abbott Laboratories •
Seegene Technologies Inc. •
Siemens Healthineers •
Exact Sciences •
Meso Scale Diagnostics LLC What’s Going on Around the Globe? • In
August 2024, Illumina received FDA approval for its "TruSight Oncology
Comprehensive," a comprehensive cancer biomarker test for tumor biomarker
diagnosis. The test is allowed to rapidly match patients to targeted
therapies based on their tumor profile. • In
August 2024, a three-day cancer Biomarkers AI and Bioinformatics Workshop was
held at Cahill Hameetman Auditorium, Caltech, Pasadena, California. This
workshop was open for members of the Early Detection Research Network, academic
researchers focusing on AI and cancer biomarkers, and industry partners. • In
June 2024, The Cancer Research UK National Biomarker Centre was officially
opened to discover, develop, validate, and qualify biomarkers in clinical
studies and trials; the National Biomarker Centre will help to bridge discovery
and clinical research. Segments Covered in the Report By Type •
Breast Cancer •
Prostate Cancer •
Colorectal Cancer •
Cervical Cancer •
Liver Cancer •
Lung Cancer •
Others By Biomolecule •
Genetic Biomarkers •
Epigenetic Biomarkers •
Metabolic Biomarkers •
Proteomic Biomarkers •
Others By Profiling Technology •
Omic Technologies •
Imaging Technologies •
Immunoassays •
Cytogenetics-based Tests By Application •
Drug Discovery and Development •
Diagnostics •
Personalized Medicine •
Others By End User •
Hospitals •
Academic and Cancer Research Institutes •
Ambulatory Surgical Centres •
Diagnostic Laboratories By Regions • North
America
o U.S.
o Canada • Europe
o U.K.
o Germany
o France • Asia-Pacific
o China
o India
o Japan
o South Korea
o Malaysia
o Philippines • Latin
America
o Brazil
o Rest of Latin America • Middle
East and Africa (MEA)
o GCC
o North Africa
o South Africa
o Rest of the Middle East and Africa Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/1637 You can place an order or ask any questions, please feel free to contact
at sales@precedenceresearch.com | +1 804 441 9344 Precedence
Research offers exclusive subscription services designed to provide in-depth
data and analytics insights. With a subscription, you gain access to a
comprehensive suite of statistical resources, market intelligence, and research
tools tailored to your business needs. Whether you're looking for industry
trends, competitive analysis, or future market projections, our subscription
plans ensure you stay ahead with reliable, up-to-date information. Browse Our Subscription Plans@ https://www.precedenceresearch.com/get-a-subscription About Us Precedence
Research is a worldwide market research and consulting organization. We give an
unmatched nature of offering to our customers present all around the globe
across industry verticals. Precedence Research has expertise in giving
deep-dive market insight along with market intelligence to our customers spread
crosswise over various undertakings. We are obliged to serve our different
client base present over the enterprises of medicinal services, healthcare,
innovation, next-gen technologies, semi-conductors, chemicals, automotive, and
aerospace & defense, among different ventures present globally. Web: https://www.precedenceresearch.com Our Blogs: Towards
Healthcare | Towards
Packaging | Statifacts | Towards EV Solutions | Towards Dental | Towards Automotive | Nova One Advisor For Latest Update Follow Us: 
